/CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay.
Approval is based on results from three Phase 3 studies: two for induction and one for maintenance 1,2,3In clinical trials, patients taking RINVOQ achieved the primary endpoint of clinical remission .
- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at. | May 9, 2023
- QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of
Timing of elimination of the hepatitis C virus (HCV) in Canada s provinces indicates 70% of provinces could reach the World Health Organization s (WHO) HCV.